靶向DLL3/CD3的双特异性抗体tarlatamab的初步数据显示良好的安全性,在经治SCLC患者中,确认的ORR为23%,其III期研究正在进行中[6]。 BCL-2拮抗剂也是潜在的治疗选择之一,但其靶向药物Navitoclax仅在针对晚期及复发SCLC的单药试验中显示...
大约 65% 的 SCLC 肿瘤具有 B7-H3 的中度至高度表达,使 B7-H3 成为有前途的治疗靶点。[14] 在IDeate-PT01 1/2 期试验中,21 例ES-SCLC 患者使用≥6.4mg/kg 的I-DXd 显示出持久疗效(客观缓解率[ORR]为 52.4%;中位缓解持续时间[DOR]为5.9 个月)。一线含铂药物治疗进展的小细胞肺癌受试者。 DS-7300...
[5] Carvajal-Hausdorf D, Altan M, Velcheti V, et al. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung cancer (SCLC)[J]. J Immunother Cancer, 2019, 7(1): 65. ...
SCLC-J1, cell line from pleural-effusion fluid in a patient with clinically advanced SCLC High levels of cell surface antigen expression patterns (floating 80.4%, adherent 85.9%) FC analysis Not evaluated [44] 115 SCLC TMA specimens Significantly high expression in TMA membranes or cytoplasms (or...
5.Porte M, Vaudron A, Crequit P, Vaugier L, Chatellier T, Fronteau C, Raimbourg J, Goronflot T, Bennouna J, Pons-Tostivint E. A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) Patie...
7MW3711, an innovative antibody-drug conjugate targeting B7-H3, has been granted an orphan drug designation by the FDA for treating small cell lung cancer. The FDA has granted 7MW3711 an orphan drug designation (ODD) for the treatment of small cell lung cancer (SCLC). 7MW3711 is a...
[0160]可以用抗-B7H3抗体治疗的转移至CNS(例如转移至软脑膜)的癌症的非限制性实例包括肉瘤、视网膜母细胞瘤、黑素瘤、卵巢癌、横纹肌肉瘤、乳腺癌和肺癌(例如小细胞肺癌(SCLC)和非小细胞肺癌(NSCLC))。在某些实施方式中, 癌症选自黑素瘤、卵巢癌、横纹肌肉瘤、乳腺癌和肺癌(例如, 小细胞肺癌(SCLC)和非小细胞...
DS-7300 administration in patients with small cell lung cancer (SCLC) shows signs of clinical efficacy (NCT05280470) [74]. In a phase 1/2 first-in-human study, clinical efficacy of DS-7300 evaluated in heavily pre-treated patients with metastatic CRPC, squamous subtype NSCLC and SCLC. ...
Expression and clinical significance of PD-L1, B7–H3, B7–H4 and TILs in human small cell lung Cancer (SCLC). J Immunother Cancer. 2019;7(1):65. 33. Yim J, Koh J, Kim S, Song SG, Ahn HK, Kim YA, Jeon YK, Chung DH. Effects of B7–H3 expression on tumour-infiltrating immune...
B7-H3 has attracted strong interest in the field of lung cancer. B7-H3 expression was found in 510 out of 634 patients with NSCLC, and a high expression level was demonstrated to have a negative impact on prognosis [122]. On the other hand, in small cell lung cancer (SCLC), B7-H3 ...